Mostrando entradas con la etiqueta DERMATOLOGIA. Mostrar todas las entradas
Mostrando entradas con la etiqueta DERMATOLOGIA. Mostrar todas las entradas
miércoles, 21 de septiembre de 2011
domingo, 28 de noviembre de 2010
ONICOMICOSIS
TIPO: REVISION
FORMATO: PDF
DESCARGA DIRECTA: DESCARGAR
TRATAMIENTO DE LA ONICOMICOSIS
Revisión publicada en la revista FORMACION MEDICA CONTINUATIPO: REVISION
FORMATO: PDF
DESCARGA DIRECTA: DESCARGAR
ESTRATEGIAS TERAPEUTICAS EN LA ONICOMICOSIS
TIPO: REVISION
FORMATO: PDF
DESCARGA DIRECTA: DESCARGAR
sábado, 2 de agosto de 2008
TRATAMIENTO DE LA HERPES SIMPLE (Revision basada en evidencia)
Revision publicada en ARCHIVES INTERNAL MEDICINE de la American Medical Association
INTRODUCCION
Genital and labial herpes simplex virus infections are frequently encountered by primary
care physicians in the United States. Whereas the diagnosis of this condition is often straightforward, choosing an appropriate drug (eg, acyclovir, valacyclovir hydrochloride, or famciclovir) and dosing regimen can be confusing in view of (1) competing clinical approaches to therapy; (2) evolving dosing schedules based on new research; (3) approved regimens of the Food and Drug Administration that may not match recommendations of the Centers for Disease Control and Prevention or of other experts; and (4) dissimilar regimens for oral and genital infections. The physician must first choose an approach to treatment (ie, intermittent episodic therapy, intermittent suppressive therapy, or chronic suppressive therapy) based on defined clinical characteristics and patient preference. Then, an evidence-based dosing regimen must be selected. In this review, data from all sources are tabulated to provide a handy clinical reference. Arch Intern Med. 2008;168(11):1137-1144.
care physicians in the United States. Whereas the diagnosis of this condition is often straightforward, choosing an appropriate drug (eg, acyclovir, valacyclovir hydrochloride, or famciclovir) and dosing regimen can be confusing in view of (1) competing clinical approaches to therapy; (2) evolving dosing schedules based on new research; (3) approved regimens of the Food and Drug Administration that may not match recommendations of the Centers for Disease Control and Prevention or of other experts; and (4) dissimilar regimens for oral and genital infections. The physician must first choose an approach to treatment (ie, intermittent episodic therapy, intermittent suppressive therapy, or chronic suppressive therapy) based on defined clinical characteristics and patient preference. Then, an evidence-based dosing regimen must be selected. In this review, data from all sources are tabulated to provide a handy clinical reference. Arch Intern Med. 2008;168(11):1137-1144.
TIPO: REVISION
FORMATO: PDF
DESCARGA DIRECTA: DOWNLOAD
Suscribirse a:
Entradas (Atom)